Testosterone for perimenopause: hype vs. what studies show

What did @ashleigh_hoke actually say?

She's 38, in perimenopause, and has been on an estradiol patch plus progesterone since February. At her three-month checkup, she told her doctor something was still "lacking in a certain department" and got prescribed a compounded testosterone gel, applied to the inner thigh at roughly 2.5 mg daily. She's also down 20 pounds and credits diet changes, not weight-loss drugs.

She was upfront that she's reporting her own experience, not giving advice. She acknowledged possible side effects like voice deepening, and noted her doctor said the low dose makes those unlikely. That kind of hedging matters. Too many hormone content creators on TikTok skip it entirely.

The main claims worth examining: that low-dose testosterone is appropriate for perimenopausal women with libido issues, that compounded testosterone gel on the thigh is a valid delivery method, and that her physical changes are plausible at this stage of treatment.

Does the science back this up?

Mostly, yes. The evidence for testosterone in women is stronger than most people realize, though still messier than the men's TRT literature. The short version: low-dose testosterone has real data behind it for hypoactive sexual desire disorder (HSDD) in women, less so for the broader "hormone optimization" framing that's everywhere on social media.

The 2019 Global Consensus Position Statement on testosterone therapy for women, published in the Journal of Clinical Endocrinology and Metabolism (Islam et al., 2019), concluded there is Level 1 evidence that testosterone improves sexual function in postmenopausal women. Perimenopause is a grayer zone, but clinically the rationale is similar: testosterone levels decline through the transition. A 2021 review in Climacteric (Davis et al.) confirmed that benefits for sexual wellbeing are reproducible across studies when doses keep levels in the normal female physiologic range. Her reported dose of approximately 2.5 mg daily is consistent with that range, though dose verification always requires bloodwork, not a TikTok caption.

The inner thigh application site for compounded gels is used clinically. It's not FDA-approved the way AndroGel is for men, but compounded testosterone for women exists precisely because no FDA-approved female testosterone product exists in the US. That gap is a real regulatory problem, not a fringe workaround.

What did they get wrong (or right)?

She got the fundamentals right. Perimenopause at 38 is real and underdiagnosed. The symptom picture she described, hot flashes mostly resolved on estrogen plus progesterone but libido still low, is a textbook presentation that warrants a testosterone conversation. Her doctor appears to be following a reasonable clinical pathway.

Where she's imprecise: she says "2.5, I think it's milligrams or grams" without knowing her own unit. That's not a safety crisis at this dose, but units matter with hormones. Milligrams and grams are not interchangeable, and compounded testosterone gels are typically dosed in milligrams per application. She should know which unit she's using.

Her hair and body composition comments are plausible but almost certainly not from one day of testosterone gel. She started the gel that morning. Hair and body composition changes from testosterone take weeks to months. The 20-pound weight loss she attributes to diet is the more credible explanation for what she's seeing right now. Giving testosterone credit on day one is premature, even if testosterone may contribute later.

What should you actually know?

Testosterone for women is legitimate medicine with real evidence, but it is not approved by the FDA for any female indication in the US. That means women who get it are using either compounded products or off-label prescribing of men's formulations at reduced doses. Both are legal and common in clinical practice, but they are not the same as an approved drug, and compounded products are not tested for bioequivalence the way brand-name drugs are.

The Endocrine Society and the International Menopause Society both acknowledge testosterone's role in female sexual dysfunction, but both also caution that long-term safety data beyond two years is limited (Wierman et al., 2014, Journal of Clinical Endocrinology and Metabolism). Side effects at supraphysiologic doses, including acne, clitoral enlargement, and voice changes, are real. Her doctor's reassurance that the dose is low enough to minimize those risks is consistent with the literature, but bloodwork to confirm levels stay in the female physiologic range is non-negotiable.

If you're in perimenopause and curious about this, the conversation belongs with a provider who will actually measure your hormone levels before and after, not someone who just scripts a gel based on a symptom checklist.